Indian #pharma firms advance all fronts across the #US 🇺🇸, according to an analysis by HSBC, and so do we at New Horizon Global Pharma (NHG Pharma) via our established branch in New Jersey. Contact us 🎯 today to learn more about our array of #APIs💊, intermediates, and pellets. HRV Global LifeSciences Hari Kiran C. Anshu Shrivastava Sreeni V https://lnkd.in/d_jDitNv
New Horizon Global Pharma (NHG Pharma)’s Post
More Relevant Posts
-
How will Biosecure Act impact Indian pharma companies? Aditya Khemka explains I do not think in the next decade or so they can shift completely from China. The idea is not to shift completely from China. The idea is to develop an alternate vendor ecosystem in event that China tries to weaponize its capabilities on the pharmaceutical raw materials side. #BiosecureAct I #APIExports I #alternatevendorecosystem I #pharma I #Market I #India I #China I Aditya Khemka Read more: https://lnkd.in/gpJmBhys
How will Biosecure Act impact Indian pharma companies? Aditya Khemka explains - ETPharma
pharma.economictimes.indiatimes.com
-
𝗜𝗻𝗱𝗶𝗮𝗻 𝗗𝗿𝘂𝗴𝗺𝗮𝗸𝗲𝗿𝘀 𝘁𝗼 𝗦𝗲𝗲 𝗙𝗬𝟮𝟱 𝗥𝗲𝘃𝗲𝗻𝘂𝗲 𝗦𝘂𝗿𝗴𝗲 𝗔𝗺𝗶𝗱 𝗨.𝗦. 𝗗𝗿𝘂𝗴 𝗦𝗵𝗼𝗿𝘁𝗮𝗴𝗲𝘀 Indian pharmaceutical companies, including Dr. Reddy's, Cipla, and Sun Pharma, are expected to see a revenue boost in FY25 due to significant drug shortages in the U.S., according to India Ratings and Research. With 233 active drug shortages across 22 therapeutic categories, U.S. regulatory challenges have curtailed production, paving the way for Indian firms to expand their supply chains and market presence. Reduced price erosion in the U.S. is also anticipated to enhance profitability. #finance #news #IndianPharma #USMarket #DrugShortages Source:- https://lnkd.in/dsiZyJaF
-
-
Top 5 Indian Pharma Stocks Poised for Growth in the Post-Biosecure Act Era #PharmacyOfTheWorld #IndianPharma #PharmaceuticalIndustry #BiosecureAct #GlobalHealthcare #PharmaInvestments #DrugManufacturing #HealthcareInnovation #PharmaExports #IndianEconomy
Top 5 Indian Pharma Stocks Poised for Growth in the Post-Biosecure Act Era #PharmacyOfTheWorld #IndianPharma #PharmaceuticalIndustry #BiosecureAct #GlobalHealthcare #PharmaInvestments #DrugManufacturing #HealthcareInnovation #PharmaExports #IndianEconomy
Top 5 Indian Pharma Stocks Poised for Growth in the Post-Biosecure Act Era | FinBrook
finbrook.in
-
https://lnkd.in/grUb8247 The Economic Survey 2023-24 tabled by the government states that the domestic pharma industry is presently valued at $50 billion and is expected to reach $130 billion by 2030. #Pharma #Tribune
Pharma supply chain requires booster dose
tribuneindia.com
-
The Indian pharmaceutical industry saw steady domestic revenue growth last fiscal. Further, it has been witnessing strong capital market and private equity interest. What does this mean for the future revenue and profitability of the pharma sector? Don’t miss the #CRISIL’s webinar on the pharma sector to get the latest industry insights. Gain insights into: ☑️ Demand drivers and outlook across markets ☑️ Growth opportunities, including biosimilars and contractual offshoring opportunities ☑️ Profitability trends of CRISIL Ratings-rated pharmaceutical firms ☑️ Outlook on credit quality Save your seat now: https://lnkd.in/dNjSMiQ9 Nitinkumar Parekh | V S MANI | Manni Kantipudi #PharmaGrowth #IndianPharma #PharmaceuticalIndustry #PharmaSector
-
-
Top 5 Indian Pharma Stocks Poised for Growth in the Post-Biosecure Act Era #PharmacyOfTheWorld #IndianPharma #PharmaceuticalIndustry #BiosecureAct #GlobalHealthcare #PharmaInvestments #DrugManufacturing #HealthcareInnovation #PharmaExports #IndianEconomy
Top 5 Indian Pharma Stocks Poised for Growth in the Post-Biosecure Act Era | FinBrook
finbrook.in
-
📊 Brickwork Ratings research insights featured in Deccan Chronicle! The article highlights improving margins in the pharmaceutical sector, projecting a positive outlook for FY25. 🌟 Explore the detailed analysis here: https://lnkd.in/gHUR6UJt #BrickworkRatings #Deccanchronicle #PharmaceuticalIndustry #FinancialResearch #EconomicOutlook #PharmaInsights #EconomicGrowth
Margins of Pharma Companies to Improve in FY25
deccanchronicle.com
-
US drugmakers are reducing their research and development investments due to a decline in innovation following the Covid-19 pandemic. In contrast, Indian pharmaceutical companies are increasing their R&D efforts to offset the impact of the post-pandemic slowdown in this sector. Domestic drug manufacturers believe that these overseas gaps could present a growth opportunity for India. In a conversation with NDTV Profit, our partner Alpana S. stated that once-thriving generic drug market is now experiencing fierce competition, which is compressing profit margins. To remain competitive, Indian companies are focusing on higher-value products that necessitate substantial R&D investment. Read the full article: https://shorturl.at/GtocZ #PharmaceuticalIndustry, #DrugManufacturing #R&DInvestment #IndianPharma #desaidiwanji
-
-
The life sciences competitiveness indicators (LSCIs) 2024 were published by Office for #LifeSciences last week, measuring the latest performance of the UK’s life sciences sector ➡ https://lnkd.in/gPugTKci The indicators demonstrate a number of strengths and weaknesses across the UK life science ecosystem and the BioIndustry Association (BIA) looks forward to working with the government to address these. Key findings from the analysis include: 📌 £9 billion of pharmaceutical R&D was performed in 2022, equivalent to 0.36% of the UK’s GDP. #Pharmaceutical R&D accounted for 18% of all R&D performed by businesses in the UK in 2022, the highest of any product area 📌 The 📍 #UK saw a further fall in the value of estimated inward life sciences FDI to £0.8 billion in 2023, ranking the UK eighth compared to comparators. Other comparators also experienced declines in 2023, including the #USA 📌 In 2022, UK’s global share of patients recruited to commercial trials was 2.6%, an increase from 2.2% in 2021 #ResearchandDevelopment
